Solutia Acquires Swiss Chemical Manufacturer

Solutia Inc. (St. Louis), a developer of chemistry-based products, has acquired AMCIS AG, a Swiss developer of production processes and manufacturer of active ingredients for clinical trials and small-volume commercial drugs. Terms of the acquisition were not disclosed.

According to John Hunter, chairman and CEO of Solutia, the acquisition enables Solutia to offer both process development expertise and a range of scale-up capabilities for active pharmaceutical ingredients, from grams to tons. In addition, it will speed the development of manufacturing processes, helping Solutia's customers get new drugs to market faster, he said.

AMCIS currently has 51 employees. The company's president and CEO, Rolf Schaufer, and other key employees will remain with AMCIS once the acquisition is complete.

AMCIS AG is a contract research, development, and manufacturing company of pharmaceutical and other fine chemicals.

Solutia Inc. makes and markets a variety of branded, chemistry-based products. The company's portfolio includes pharmaceutical fine-chemicals; performance films; resins and additives; nylon intermediates, polymers, and fibers; and specialty products.

For more information: John Hunter, Chairman and CEO, Solutia Inc., 575 Maryville Centre Dr. PO Box 66760, St. Louis, MO 63166-6760. Tel: 314-674-1000. Fax: 314-694-8686.

Edited by Jim Pomager